Halogenated benzimidazole carboxamides target integrin α 4β1 on T-cell and B-cell lymphomas

Cancer Research

Volumn 70, Issue 13, 2010, Pages 5448-5456

  Carpenter, Richard D ^a,e   Natarajan, Arutselvan ^c,f   Lau, Edmond Y ^d   Andrei, Mirela ^c   Solano, Danielle M ^a   Lightstone, Felice C ^d   DeNardo, Sally J ^b   Lam, Kit S ^c   Kurth, Mark J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^e University of California   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (5 BROMO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZOIC ACID; 4 (5 CHLORO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZOIC ACID; 4 (5 FLUORO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZOIC ACID; 4 (5 IODO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZOIC ACID; 5 [2 [4 (5 BROMO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZAMIDO]] 6 [3 (PYRIDIN 3 YL)ACRYLAMIDO)HEXANAMIDO] 6 [1 (1,6 DIAMINO 1 OXOHEXAN 2 YLCARBAMOYL)CYCLOHEXYLAMINO] 6 OXOHEXANOIC ACID; 5 [2 [4 (5 BROMO 1H BENZO[D]IMIDAZOL 2 YLAMINO]BENZAMIDO] 6 [[3 (PYRIDIN 3 YL)ACRYLAMIDO]HEXANAMIDO] 6 (1 CARBAMOYLCYCLOHEXYLAMINO) 6 OXO HEXANOIC ACID; 6 (1 CARBAMOYLCYCLOHEXYLAMINO) 5 [2 [4 (5 CHLORO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZAMIDO]] 6 [[3 (PYRIDIN 3 YL)ACRYLAMIDO]HEXANAMIDO] 6 OXO HEXANOIC ACID; 6 (1 CARBAMOYLCYCLOHEXYLAMINO) 5 [2 [4 (5 FLUORO 1H BENZO[D]IMIDAZOL 2 YL)AMINO]BENZAMIDO] 6 [3 (PYRIDIN 3 YL ACRYLAMIDO)HEXANAMIDO] 6 OXO HEXANOIC ACID; 6 (1 CARBAMOYLCYCLOHEXYLAMINO) 5 [2 [4 (5 IODO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZAMIDO]] 6 [[3 (PYRIDIN 3 YL)ACRYLAMIDO]HEXANAMIDO] 6 OXOHEXANOIC ACID; 6 (1 CARBAMOYLCYCLOHEXYLAMINO) 5 [2 [4 (5 IODO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZAMIDO]] 6 [[3 (PYRIDIN 3 YL)ACRYLAMIDO]HEXANAMIDO] 6 OXOHEXANOIC ACID I 125; 6 [1 [1 AMINO 6 (4 IODOBENZAMIDO) 1 OXOHEXAN 2 YLCARBAMOYL]CYCLOHEXYLAMINO] 5 [2 [4 (5 BROMO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZAMIDO]] 6 [[3 (PYRIDIN 3 YL)ACRYLAMIDO]HEXANAMIDO] 6 OXOHEXANOIC ACID I 125; 6 [1 [3 AMINO 2 (4 HYDROXY 3 IODOBENZYL) 3 OXOPROPANOYLCARBAMOYL]CYCLOHEXYLAMINO] 5 [2 [4 (5 BROMO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZAMIDO]] 6 [[3 (PYRIDIN 3 YL)ACRYLAMIDO]HEXANAMIDO] 6 OXOHEXANOIC ACID I 125; 6 [1 [3 AMINO 2 (4 HYDROXYBENZYL) 3 OXOPROPANOYLCARBAMOYL]CYCLOHEXYLAMINO] 5 [2 [4 (5 BROMO 1H BENZO[D]IMIDAZOL 2 YLAMINO)BENZAMIDO]] 6 [[3 (PYRIDIN 3 YL)ACRYLAMIDO]HEXANAMIDO] 6 OXOHEXANOIC ACID; BENZIMIDAZOLE DERIVATIVE; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; HALOBENZIMIDAZOLE CARBOXAMIDE DERIVATIVE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CELL ADHESION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; MICROWAVE IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIODINATION; RAJI CELL; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; BENZIMIDAZOLES; FEMALE; FLUORINE RADIOISOTOPES; INTEGRIN ALPHA4BETA1; IODINE RADIOISOTOPES; ISOTOPE LABELING; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RADIOPHARMACEUTICALS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954374488     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3736     Document Type: Article

References (48)

1. Hait WN. Targeted cancer therapeutics. Cancer Res 2009;69: 1263-7.
2. Shimaoka M, Takagi J, Springer TA. Conformational regulation of integrin structure and function. Annu Rev Biophys Biomol Struct 2002;31:485-516. (Pubitemid 34666842)
3. 1 integrin for in vivo tumor imaging. Nat Chem Biol 2006;2:381-9.
4. Martin KH, Slack JK, Boerner SA, Martin CC, Parsons T. Integrin connections map: to infinity and beyond. Science 2002;296:1652-3.
5. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 2002;22:146-67. (Pubitemid 34160583)
6. Vincent AM, Cawley JC, Burthem J. Integrin function in chronic lymphocytic leukemia. Blood 1996;87:4780-8. (Pubitemid 26162379)
7. Marco RA, Diaz-Montero CM, Wygant JN, Kleinerman ES, McIntyre BW. α4 integrin increases anoikas of human osteosarcoma cells. J Cell Biochem 2003;88:1038-47.
8. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic- cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003;9: 1158-65.
9. Olson DL, Burkly LC, Leone DR, Dolinsky BM, Lobb RR. Anti-α4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther 2005;4:91-9.
10. 4β1- VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J Clin Invest 2005;115: 1542-51.
11. Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J. Integrin α4β1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res 2006;66:2146-52.
12. 4β1 integrin receptor in non-Hodgkin's lymphoma. Lett Pept Sci 2002;8:171-8.
13. 4β1 integrin. J Med Chem 2007;50:5863-7.
14. 4β1 integrin. Mol Cancer Ther 2008;7:432-7.
15. 4β1 integrin. J Med Chem 2009;52:14-9.
16. 4β1 integrin: comparative pharmacokinetics for imaging and therapy of lymphoid malignancies. J Nucl Med 2009; 50:625-34.
17. Aina OH, Liu R, Sutcliffe JL, Marik J, PanC-X, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm 2007;4:631-51.
18. Perkins JJ, Zartman AE, Meissner RS. Synthesis of 2-(alkylamino) benzimidazoles. Tetrahedron Lett 1999;40:1103-6.
19. Katritzky AR, Witek RM, Rodriguez-Garcia V, et al. Benzotriazole-assisted thioacylation. J Org Chem 2005;70:7866-81.
20. 4β1 integrin prevents apoptosis in B-cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999;13:266-74.
21. 123I]-2-iodo-L-tyrosine. Nucl Med Biol 2006;33:111-7.
22. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding of fibrinogen-mimetic therapeutics. Nature 2004;432:59.
23. Margelevicius M, Venclovas C. PSI-BLAST-ISS: an intermediate sequence search tool for estimation of the position-specific alignment reliability. BMC Bioinformatics 2005;6:185.
24. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389.
25. Sali A, Blundell TL. Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 1993;234:779.
26. Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639.
27. Jackalian A, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. parameterization and validation. J Comput Chem 2002;23:1623.
28. Weiner SJ, Kollman PA, Case DA, et al. A new force field for molecular simulation of nucleic acids and proteins. J Am Chem Soc 1984; 106:765.
29. Legge GB, Morris GM, Sanner MF, Takada Y, Olson AJ, Grynszpan F. Model of the α L β 2 integrin I-domain/ICAM-1 DI interface suggest that subtle changes in loop orientation determine ligand specificity. Proteins: Struct Funct Genet 2002;48:151.
30. Carpenter RD, DeBerdt PB, Lam KS, Kurth MJ. A carbodiimide-based library method. J Comb Chem 2006;8:907-14.
31. Carpenter RD, Lam KS, Kurth MJ. Microwave-mediated heterocyclization to benzimidazo[2,1-b]quinazolin-12(5H)-ones. J Org Chem 2007;72:284-7.
32. Carpenter RD, Fettinger JC, Lam KS, Kurth MJ. Asymmetric catalysis: polystyrene-bound hydroxyprolylthreonine in the enamine-mediated preparation of chromanones. Angew Chem 2008;120: 6507-10;
33. Angew Chem Int Ed 2008;47:6407-10.
34. Biotage microwave conversion chart. Available from: http://www. biotage.com/DynPage.aspx?id=21996.
35. Martin EJ, Critchlow RE. Beyond mere diversity: tailoring combinatorial libraries for drug discovery. J Comb Chem 1999;1:32-45.
36. Lu Y, Yong W, Xu Z, et al. C-X.H contacts in biomolecular systems: how they contribute to protein-ligand binding affinity. J Phys Chem B 2009;113:12615-21.
37. Auffinger P, Hays FA, Westhof E, Ho PS. Halogen bonds in biological molecules. Proc Natl Acad Sci U S A 2004;101:16789-94.
38. Tawarada R, Seio K, Sekine M. Synthesis and properties of oligonucleotides with iodo-substituted aromatic aglycons: investigation of possible halogen bonding base pairs. J Org Chem 2008;73:383-90.
39. Peet JH. How big is an atom? Phys Educ 1975:508-10.
40. Kiyono Y, Kanegawa N, Kawashima H, Kitamura Y, Iida Y, Saji H. Evaluation of radioiodinated (R)-N-methyl-3-(2-iodophenoxy)-3- phenylpropanamine as a ligand for brain norepinephrine transporter imaging. Nucl Med Biol 2004;31:147-53.
41. Araujo EB, Santos JS, Colturato MT, Muramoto E, Silva CPG. Optimization of a convenient route to produce N-succinimidyl 4-radiodobenzoate for radioiodination of proteins. Appl Radiat Isot 2003;58:667-73.
42. Klapers A, Buchwald SL. Copper-catalyzed halogen exchange in aryl halides: an aromatic Finkelstein reaction. J Am Chem Soc 2002;124: 14844-5.
43. Garg PK, Slade SK, Harrison CL, Zalutsky MR. Labeling proteins using aryl iodide acylation agents: influence of meta vs para substitution on in vivo stability. Nucl Med Biol 1989;16:669-73.
44. Wilbur DS, Hamlin DK, Chyan M-K, Kegley BB, Quinn J, Vessella RJ. Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl- biotin derivatives. Bioconjug Chem 2004;15:601-16.
45. 3 Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Intl J Cancer 2008;123:709-15.
46. Fernandes C, Oliveira C, Gano L, Bourkoula A, Pirmettis I, Santos I. Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer. Bioorg Med Chem 2007;15: 3974-80.
47. Smallridge RC, Burman KD, Ward KE, et al. 3′,5′- Diiodothyronine to 3′-monoiodothyronine conversion in the fed and fasted rat: Enzyme characteristics and evidence for two distinct 5′-deiodinases. Endocrinology 1981;108:2336-45.
48. 127/125I]iodobenzoate involving a microwave-accelerated iodination step. J Labelled Comp Radiopharm 2001; 44:235-40.